SMITH & NEPHEW PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 990.4 GBX | +0.30% |
|
+1.19% | -8.17% |
| May. 31 | SMITH & NEPHEW : EPS cut (2023: +8.0%, 2024: -16.2%) |  |
| May. 14 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading | MT |
Financials (USD)
| Sales 2024 * | 5.82B | Sales 2025 * | 6.12B | Capitalization | 10.99B |
|---|---|---|---|---|---|
| Net income 2024 * | 540M | Net income 2025 * | 693M | EV / Sales 2024 * | 2.33 x |
| Net Debt 2024 * | 2.56B | Net Debt 2025 * | 2.23B | EV / Sales 2025 * | 2.16 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
16.4
x | Employees | 18,452 |
| Yield 2024 * |
3% | Yield 2025 * |
3.38% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More recommendations
More press releases
More news
| 1 day | +0.30% | ||
| 1 week | +1.19% | ||
| 1 month | +1.16% | ||
| 3 months | -4.81% | ||
| 6 months | -3.23% | ||
| Current year | -8.17% |
1 week
968.20
995.81
1 month
967.801 033.50
Current year
946.001 181.50
1 year
887.001 269.00
3 years
887.001 601.50
5 years
887.002 023.00
10 years
881.002 023.00
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 14 M€ | -5.07% | ||
| 0.52% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 990.4 | +0.30% | 9,707,275 |
| 24-05-30 | 987.4 | +0.73% | 1,998,978 |
| 24-05-29 | 980.2 | +0.02% | 2,682,760 |
| 24-05-28 | 980 | +0.12% | 2,332,723 |
| 24-05-24 | 978.8 | -0.39% | 3,084,127 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.6
USD
Average target price
16.35
USD
Spread / Average Target
+29.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.17% | 10.99B | |
| +13.73% | 130B | |
| -4.33% | 8.35B | |
| +41.80% | 5.67B | |
| -21.94% | 4.72B | |
| +7.81% | 3.42B | |
| -10.26% | 2.76B | |
| -10.29% | 2.11B | |
| -13.58% | 1.92B | |
| -27.77% | 1.68B |
- Stock Market
- Equities
- SN. Stock
